CME Information

Symposium Director

E. Michael Lewiecki, MD

  • Director
  • New Mexico Clinical Research & Osteoporosis Center
  • Clinical Assistant Professor of Medicine
  • University of New Mexico School of Medicine
  • Albuquerque, NM

Faculty

John P. Bilezikian, MD

  • Professor of Medicine and Professor of Pharmacology
  • College of Physicians and Surgeons
  • Columbia University
  • Chief of Endocrinology & Director of Metabolic Bone Diseases Program
  • Columbia University Medical Center
  • New York City, NY

Sundeep Khosla, MD

  • Distinguished Investigator
  • Mayo Foundation
  • Research Professor of Medicine & Physiology
  • Dr. Francis Chucker and Nathan Landow
  • Associate Director for Research
  • College of Medicine, Mayo Clinic
  • Rochester, MN
Robert Marcus

Robert Marcus, MD

  • Consultant
  • Santa Fe, NM
Michael McClung

Michael McClung, MD

  • Director
  • Oregon Osteoporosis Center
  • Portland, OR

Paul D. Miller, MD

  • Distinguished Clinical Professor of Medicine
  • University of Colorado Health Sciences Center
  • Director
  • Colorado Center for Bone Research
  • Lakewood, CO

Nelson B. Watts, MD

  • Professor of Medicine
  • University of Cincinnati College of Medicine
  • Director
  • University of Cincinnati Bone Health and Osteoporosis Center
  • Cincinnati, OH

Technology Faculty

Isabel Torres, RT(R), CDT

  • DXA Technologist/Recruiter
  • New Mexico Clinical Research & Osteoporosis Center
  • Albuquerque, NM
Annette Torrez

Annette Torrez, RT, (R)(M)(BD), CDT

  • Lead Technologist for Radiology/Bone Densitometry
  • Presbyterian Medical Group
  • Albuquerque, NM

Daniel E. Widholm, RT (R)(BD), CDT

  • Site Manager and Lead Technologist
  • New Mexico Osteoporosis Center
  • Albuquerque, NM

Learning Objectives

This activity is designed for physicians who treat postmenopausal women or other patients at risk for osteoporosis. There are no prerequisites for this activity. At the conclusion of this activity, participants should be able to:

  • Employ consistently the current guidelines for osteoporosis screening and assessment.
  • Make appropriate use of FRAX to define fracture risk.
  • Describe age- and gender-related changes in bone micro- and macro-architecture, the pathogenesis of skeletal fragility, and the implications these have on clinical care.
  • Employ BTM to assess response to treatment and monitor patient compliance.
  • Discuss emerging data on the use of PTH in combination with other agents and in diverse settings.
  • Discuss with patients the benefits and risks of long-term bisphosphonate therapy.
  • Discuss current expert recommendations for drug holidays for patients taking bisphosphonates long-term.
  • Compare current and emerging therapies including their mechanisms of action, efficacy, safety, and administration for patients with osteoporosis.
  • Consider options for timing and sequencing treatment using antiresorptive and anabolic agents to maximize their unique benefit particularly in patients at highest fracture risk.
  • Apply current insights in treatment to optimize bone health in complex cases.Apply current insights in treatment to optimize bone health in complex cases.

CME Information

Release Date: September 15, 2010.

Valid for credit through September 14, 2011.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine and Health Focus, Inc. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Indiana University School of Medicine designates this educational activity for a maximum of 19 AMA PRA Category 1 Credit(s).TM Physicians should only claim credit commensurate with the extent of their participation in the activity.

To receive credit, participants must listen to the audio recordings, view the slides, and read the newsletter; and complete the activity evaluation form and posttest (passing score = 70% or higher).

Length of time to complete the activity: 19 hours.

Faculty Disclosure

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. John P. Bilezikian, MD, has served as a consultant: for Alliance for Better Bone Health, Merck, Eli Lilly, Novartis, Johnson & Johnson, NPS Pharmaceuticals, Amgen; and speaker for Alliance for Better Bone Health, Eli Lilly, Novartis. E. Michael Lewiecki, MD, has received research funding from Amgen, Eli Lilly, GSK, Novartis, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Wyeth; served on the Scientific Advisory Boards for Amgen, Eli Lilly, Novartis, Roche/GSK, Upsher-Smith, Wyeth and speakers’ bureaus for Eli Lilly, Novartis, Roche/GSK; and has ownership Interest in General Electric, Procter & Gamble, Teva. Robert Marcus, MD, has received honorarium from Eli Lilly and consulting fees from Amgen. Michael McClung, MD, has received honoraria from Amgen, Lilly, Merck, Novartis, Warner Chilcott. Paul D. Miller, MD has received grant funding from Procter & Gamble, sanofi-aventis, Roche, Eli Lilly, Merck, Novartis, Amgen; speaker fees from Procter & Gamble, sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche/GlaxoSmithKline; served as a consultant for Procter & Gamble, sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche/GlaxoSmithKline, and on the speakers bureau for Procter & Gamble, sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche/GlaxoSmithKline. Nelson B. Watts, MD has received honoraria from Amgen, Novartis, Proctor & Gamble, sanofi-aventis; and served as a consultant for Amgen, Baxter, Eli Lilly, InteKrin, Johnson & Johnson, MannKind, Novartis, Novo Nordisk, Procter & Gamble, sanofi-aventis, Takeda Pharmaceuticals; and received research funding from Amgen, Eli Lilly, Merck, Novartis, Ortho-McNeil Janssen, Procter & Gamble. The following have reported no financial relationships to disclose: Sundeep Khosla, MD, Isabel Torres, RT(R), CDT, Annette Torrez, RT, (R)(M)(BD), CDT, Daniel E. Widholm, RT (R)(BD), CDT.

NOTICE: Indiana University School of Medicine advises the participant that this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.